Caris Life Sciences, Inc. (CAI)

CIK 0002019410 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-08-05) · 99.1
Q1-2026 8-K (2026-05-07) · 99.1
Latest FY-2025 8-K (2026-02-26) · 99.1  |  8-K (2026-01-12) · 99.1
Q3-2025 8-K (2025-11-05) · 99.1
Q2-2025 8-K (2025-08-12) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
Audit Information
—
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Condensed Consolidated Statements of Operations and Comprehensive Income (loss) (unaudited)
—
Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Shareholders Deficit (unaudited)
—
Consolidated Statements of Redeemable Convertible Preferred Stock and Shareholders Equity (deficit)
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Shareholders Deficit (unaudited) (P)
—
Consolidated Statements of Redeemable Convertible Preferred Stock and Shareholders Equity (deficit) (P)
Consolidated Statements of Cash Flows
Notes
Commitment and Contingencies
Consolidated Balance Sheet and Statement of Operations and Comprehensive Loss Components
Cybersecurity Risk Management and Strategy Disclosure
—
Employee Benefit Plan
Income Taxes
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Leases
Long-term Debt
Nature of The Business
Net Income (loss) Per Share Attributable To Common Shareholders
—
Net Loss Per Share Attributable To Common Shareholders
Redeemable Convertible Preferred Stock
Related Parties
Restricted Cash
Segment and Geographic Information
Shareholders Equity and Equity Compensation
Subsequent Events
Summary of Significant Accounting Policies and Estimates